Welcome to our dedicated page for CLOVER HEALTH INVESTMENTS /DE SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOVER HEALTH INVESTMENTS /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOVER HEALTH INVESTMENTS /DE's regulatory disclosures and financial reporting.
CLOV lists proposed sale of 2,360 Restricted Stock Units on 06/15/2026. The filing also discloses recent 10b5-1 sales by Jamie Reynoso totaling 19,472 shares across 03/18/2026, 06/11/2026, and 06/15/2026 with disclosed gross amounts.
Clover Health Investments vice president of finance and controller Joseph Frank Oldakowski reported an open-market sale of 12,102 shares of Class A Common Stock at $4.86 per share. After this transaction, he directly holds 299,067 shares.
According to the footnote, these shares were sold to cover tax withholding obligations tied to the vesting of 25% of restricted stock units granted on June 16, 2025. The remaining RSUs vest in equal 6.25% quarterly installments through June 16, 2029, subject to his continued service, and the sale is described as a mandatory “sell to cover” rather than a discretionary trade.
Clover Health Investments, Corp. filed a Form 144 reporting the sale of 14,155 shares of Class A Common Stock in connection with the vesting of restricted stock units on 06/16/2026.
The filing lists the securities as traded on Nasdaq and identifies the transaction as compensation-related vesting. The filing is a resale notice under Rule 144.
Clover Health Investments, Corp. reported that on June 15, 2026, Brady Priest decided to step down as Chief Executive Officer of Clover Care Services, its home-care business, effective July 3, 2026. The company will not name a new CEO for this unit. Instead, Priest’s prior responsibilities will be reorganized and distributed among members of Clover Health’s existing executive leadership team to more closely integrate Clover Care Services with the broader business. The company stated that Priest’s departure is not due to any disagreement regarding operations, policies, or practices. Clover also included standard forward-looking statement language emphasizing that anticipated benefits from the new organizational structure are subject to risks and uncertainties outlined in its SEC filings.
Clover Health Investments’ Chief Legal Officer Karen Soares reported a mandated share sale tied to tax withholding. She sold 4,681 shares of Class A common stock in open-market transactions at a weighted average price of about $4.61 per share, with trades ranging from $4.61 to $4.64.
The company’s equity incentive plan required these “sell to cover” transactions to satisfy tax obligations from vesting restricted stock units, so they were not discretionary trades. Following the sale, Soares directly holds 1,567,741 shares of Clover Health Class A common stock.
Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, reported a small sale of Class A common stock. On June 15, 2026, Reynoso sold 6,350 shares in open-market transactions at a weighted average price around $4.61 per share.
According to the disclosure, these shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units under the company’s equity incentive plans, and are described as non-discretionary “sell to cover” transactions. After this activity, Reynoso directly holds 2,843,571 shares of Clover Health Class A common stock.
Clover Health Investments, Corp. reported a proposed sale of Class A Common Stock tied to the vesting of Restricted Stock Units on 06/15/2026. The filing lists 5,342 shares and references Nasdaq as the market.
Clover Health Investments, Corp. files a Form 144 notice for Class A Common Stock related to the vesting of restricted stock units. The filing lists 7,556 shares of Class A Common Stock with a proposed sale date of 06/15/2026. The excerpt also shows prior sales by Jamie Reynoso of 5,833 shares on 03/18/2026 and 7,289 shares on 06/11/2026.
Clover Health Investments, Corp. reported results from its 2026 annual stockholder meeting held virtually on June 10, 2026. Stockholders elected three Class II directors — Demetrios L. Kouzoukas, Andrew Toy, and Thomas L. Tran — to serve until the 2029 annual meeting.
Stockholders approved, on a non-binding advisory basis, the 2025 compensation of the company’s named executive officers, with over one billion votes cast in favor. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, reported an open-market sale of Class A Common Stock. Reynoso sold 7,289 shares at a weighted average price of $4.91 per share under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Reynoso directly holds 2,849,921 shares, so the sale represents a small portion of her overall position.